Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by inthnoon Mar 21, 2002 11:27am

235 Views

Post# 4909376

RE: HCand FDA

HC application for phase 1-2 glio was 1/24/02.The turnaround time for intial response is 30 days.The governing bodies which are very busy usually wait the full thirty and then ask the questions.They then have another 30 days and so on and so on. As I understand it progress is coming along just fine with HC and I understand that they have been very forthcoming in trying to help as much as possible. Inthno

Bullboard Posts

A junior copper-gold stock trading at a bargain of monumental proportions